https://finance.yahoo.com/amphtml/news/aytu-bioscience-investigated-possible-securities-133736495.html

Aytu BioScience Investigated for Possible Securities Laws Violations; Investors Who Lost Money Should Contact Block & Leviton

GlobeNewswire

April 17, 2020, 8:37 am

BOSTON, April 17, 2020 (GLOBE NEWSWIRE) – Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, is investigating Aytu BioScience, Inc. (AYTU) and certain of its officers for potential securities fraud. Investors who purchased Aytu shares should contact Block & Leviton for a free case evaluation.

Aytu is a specialty pharmaceutical company focused on global commercialization of products addressing a variety of medical needs. On March 10, 2020, Aytu reported that it reached a license agreement for the exclusive distribution of a point-of-care rapid test for certain COVID-19 antibodies in the U.S. for three years, with three year auto-renewals thereafter. On this news, the price of Aytu’s stock soared 322%.

This morning, before the markets opened, NBC News issued a report entitled “Unapproved Chinese coronavirus antibody tests being used in at least 2 states.” This article reported that Aytu has been distributing tests from unapproved Chinese manufacturers, citing health officials and FDA filings. The report noted that these tests were shipped to the US after the FDA relaxed its guidelines for tests in mid-March. According to the article, unreliable tests can produce false results. The stock has already dropped significantly in premarket trading.

_-----

Article mentioned in previous article

Aytu selling unapproved antibody tests to us

https://www.nbcnews.com/health/health-news/unapproved-chinese-coronavirus-antibody-tests-being-used-least-2-states-n1185131

In early April, Aytu Bioscience supplied tests to the Denver Public Safety Department, according to a company news release and Kelli Christensen, a spokeswoman for the Public Safety Department, which oversees the city's first responders.

In a phone call Monday, Christensen said that the Aytu tests had been in use as a screening tool for a week and that she had heard anecdotally that they were generating a considerable number of false positives early on.

"There have been more presumptive positives than confirmed cases," Christensen said.

---+-

Press release from aytu

https://www.accesswire.com/585177/Aytu-BioScience-Provides-Update-on-its-Licensed-COVID-19-IgGIgM-Rapid-Test-Supply-and-Ongoing-US-Distribution

We are pleased that the manufacturer has completed this second order, which is now awaiting customs clearance. Further, we have been informed the manufacturer has accepted another purchase order, which

----

Aytu giving faulty tests to our first responders

https://247wallst.com/healthcare-business/2020/04/16/aytu-bioscience-stock-developments-in-denver/amp/

The Situation in Denver

Aytu Bio has produced 100,000 COVID-19 rapid tests, and there are 500,000 more on the way. Denver will be the first beneficiary of these tests, namely its first responders at the point of care.

In a recent press release, Aytu announced:

[Aytu BioSciences,] a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs was featured on a FOX segment titled: “Denver officers, firefighters will be among first in US to get rapid COVID-19 tests,” reported on by affiliated television station in Denver, Colorado, KDVR; and on an NBC segment titled “Denver scores 2,700 COVID-19 rapid tests for first responders – Aytu Bioscience in Englewood has 100,000 tests ready to ship across the country with 500,000 more on the way,” reported on by affiliated television station in Denver, Colorado, 9News.

_---—

March 10

signed an exclusive distribution agreement for the right to commercialize a clinically validated and commercially used coronavirus 2019 (COVID-19) IgG/IgM Rapid Test. The test has been licensed from L.B. Resources, Limited (a Hong Kong Corporation), which licensed North American rights from product developer Zhejiang Orient Gene Biotech Co., Ltd. The test is intended for professional use and delivers clinical results between 2 and 10 minutes at the point-of-care. This exclusive agreement grants Aytu the exclusive right to distribute the product in the United States for a period of three years, with additional three-year autorenewals thereafter.

https://finance.yahoo.com/amphtml/news/aytu-bioscience-secures-exclusive-u-120500962.html

_---

Stock info

Big armistice sell off

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aytu/aytu-bioscience

_-—

Aytu BioScience (AYTU) Appoints Steven Boyd to Board

April 16, 2019 11:22 AM

Aytu BioScience, Inc. (NASDAQ: AYTU) today announced the formal appointment of Steven Boyd, Founder and Chief Investment Officer of Armistice …

>>9050018

_--–

Among these funds, Armistice Capital held the most valuable stake in Aytu BioScience, Inc. (NASDAQ:AYTU), which was worth $6.2 million at the end of the third quarter. On the second spot was Wexford Capital which amassed $0.1 million worth of shares. Citadel Investment Group was also very fond of the stock, becoming one of the largest hedge fund holders of the company. In terms of the portfolio weights assigned to each position Armistice Capital allocated the biggest weight to Aytu BioScience, Inc. (NASDAQ:AYTU), around 0.41% of its 13F portfolio. Wexford Capital is also relatively very bullish on the stock, designating 0.02 percent of its 13F equity portfolio to AYTU.

_---

Mr. Boyd is the Chief Investment Officer of Armistice Capital, a healthcare equity hedge fund he has built to over $800M in assets under management since Armistice's founding in 2012. Prior to founding Armistice, Mr. Boyd was a Research Analyst at Senator Investment Group, York Capital, and SAB Capital Management, where he focused on healthcare. Mr. Boyd began his career as an Analyst at McKinsey & Company. Mr. Boyd has served as a member of the board of directors of Cerecor (CERC), an integrated biopharmaceutical company focused on pediatric healthcare, since April 2017 and EyeGate Pharmaceuticals (EYEG), a clinical-stage, specialty pharmaceutical company focused on disorders of the eye, since May 2018. Mr. Boyd received a B.S. in Economics and a B.A. in Political Science from The Wharton School of the University of Pennsylvania.

Steven Boyd stated, "Josh and the Aytu team have transformed the Company over the last six months. I look forward to joining the board and working closely with them to drive long-term, sustainable shareholder value."

https://www.accesswire.com/529536/Aytu-BioScience-Announces-Appointment-of-Two-New-Directors-Steven-Boyd-and-Ketan-Mehta

_---–

https://finance.yahoo.com/amphtml/news/aytu-bioscience-signs-exclusive-global-120000824.html

Healight

https://www.justice.gov/opa/speech/attorney-general-william-p-barr-delivers-19th-annual-barbara-k-olson-memorial-lecture

Bill Barr insurgency

Speech from Nov 2019

Immediately after President Trump won election, opponents inaugurated what they called “The Resistance,” and they rallied around an explicit strategy of using every tool and maneuver available to sabotage the functioning of his Administration. Now, “resistance” is the language used to describe insurgency against rule imposed by an occupying military power. It obviously connotes that the government is not legitimate. This is a very dangerous – indeed incendiary – notion to import into the politics of a democratic republic. What it means is that, instead of viewing themselves as the “loyal opposition,” as opposing parties have done in the past, they essentially see themselves as engaged in a war to cripple, by any means necessary, a duly elected government.

https://nypost.com/2019/11/16/barr-accuses-liberal-resistance-of-trying-to-sabotage-trump/